









Markets
/
Stocks
/
nasdaq-csci
/

COSCIENS Biopharma Inc

CSCI

2.720USD

0.000

Close 09/19, 16:00（ET）Quotes delayed by 15 min

8.64MMarket Cap

LossP/E TTM



COSCIENS Biopharma Inc

2.720

0.000

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-03

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. The company is performing strongly in the stock market, with strong fundamentals and technicals supporting the momentum. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

276 / 689

Overall Ranking

423 / 4737

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 0 analysts

Current Rating

Target Price

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

COSCIENS Biopharma Inc., formerly Aeterna Zentaris Inc., is a specialty biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of pharmaceutical and diagnostic products, including those focused on areas of unmet medical need. Its lead product, macimorelin (Macrilen; Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The Company is also engaged in the development of therapeutic assets and proprietary extraction technology, which is applied to the production of active ingredients from renewable plant resources used in cosmeceutical products (i.e., oat beta glucan and avenanthramides, which are found in skincare product brands like Aveeno and Burt’s Bees formulations) and being developed as potential nutraceuticals and/or pharmaceuticals.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 69.98% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 9.59M.

Fairly Valued

The company’s latest is -0.42, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 331.27K shares, decreasing 2.04% quarter-over-quarter.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of -0.11.

Financial Health

Currency: USD Updated: 2025-09-03

The company's current financial score is 7.68, which is higher than the Biotechnology & Medical Research industry's average of 6.80. Its financial status is robust, and its operating efficiency is average. Its latest quarterly revenue reached 1.50M, representing a year-over-year increase of 37400.00%, while its net profit experienced a year-over-year increase of 36.46%.

Score

Industry at a Glance

Previous score

7.68

Change



Financials



Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings



Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency



Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential



Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns



Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-03

The company’s current valuation score is 1.20, which is lower than the Biotechnology & Medical Research industry's average of 1.64. Its current P/E ratio is -0.48, which is -28.00% below the recent high of -0.34 and -26.70% above the recent low of -0.61.

Score

Industry at a Glance

Previous score

1.20

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 276/689

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-03

There is no earnings forecast score for this company; the Biotechnology & Medical Research industry's average is 7.96.

Score

Industry at a Glance

Previous score

0.00

Change

Support & Resistance

No Data

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-03

The company’s current price momentum score is 6.55, which is lower than the Biotechnology & Medical Research industry's average of 6.80. Sideways: Currently, the stock price is trading between the resistance level at 3.95 and the support level at 2.44, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.62

Change

-0.45

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(6)

Neutral(1)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.007

Sell

RSI(14)

37.367

Neutral

STOCH(KDJ)(9,3,3)

39.481

Sell

ATR(14)

0.351

High Vlolatility

CCI(14)

-100.039

Sell

Williams %R

77.551

Sell

TRIX(12,20)

-0.979

Sell

StochRSI(14)

0.000

Sell

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

3.028

Sell

MA10

2.984

Sell

MA20

3.157

Sell

MA50

3.499

Sell

MA100

3.458

Sell

MA200

3.186

Sell

Institutional Confidence

Currency: USD Updated: 2025-09-03

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Goodwood Inc.

257.26K

Gagnon (Gilles R)

41.96K

Susquehanna International Group, LLP

11.91K

RBC Dominion Securities, Inc.

3.87K

-1.75%

TD Waterhouse Canada, Inc.

3.72K

Desjardins Securities Inc.

2.81K

-27.39%

Li (William W. M.D.)

2.40K

UBS Financial Services, Inc.

2.34K

+240.67%

Kosciessa (Ulrich)

1.85K

National Bank of Canada

1.12K

-81.05%

Risk Assessment

Currency: USD Updated: 2025-09-03

The U.S. Dollar Index is currently in a neutral state, which has a minor effect on the Biotechnology & Medical Research mixed industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The company’s current risk assessment score is 3.88, which is higher than the Biotechnology & Medical Research industry's average of 3.51. The company's beta value is 1.90. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.